NEW YORK (GenomeWeb News) — Epigenomcs and Qiagen today announced an option agreement allowing Qiagen to develop a colorectal cancer blood test based on Epigenomics' mSept9 biomarker and certain DNA methylation analysis technologies.
Qiagen has two years to exercise its option under the non-exclusive license granted by Epigenomics. Qiagen also has received a research license covering the mSept9 biomarker and technologies, and it is currently developing sample preparation technology "that meets the requirements for the future broad implementation of methylation-based molecular diagnostics," such as Septin-9 targeted blood testing for colorectal cancer on Qiagen's QIAsymphony platform, Epigenomics said in a statement
Epigenomics is providing expertise and aiding in the collection of clinical specimens during the R&D phase, for which it will receive reimbursement from Qiagen.
Epigenomics also will receive an upfront payment, under the terms of the deal, and a license payment from Qiagen upon exercise of the option. If Qiagen commercializes a test based on Epigenomics' biomarkers and technologies, it will pay Epigenomics royalties on net sales and certain commercial milestone payments if specific revenue targets are reached.
Further financial terms were not disclosed.
The two companies have collaborated since 2005, when they signed a licensing and OEM agreement to develop products for DNA methylation analysis.